Intuitive Surgical Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw all board nominees elected and all proposals approved, including executive compensation and auditor ratification. Strong financial results were reported for 2025 and Q1 2026, with continued focus on global expansion, innovation, and manufacturing optimization amid competitive and geopolitical challenges.
-
Q1 delivered 17% procedure growth and 23% revenue growth, with strong U.S. and European performance and robust adoption of da Vinci 5, Ion, and SP platforms. Guidance for 2026 was raised, and innovation-led revenue growth outpaced procedures, supported by digital and AI investments.
-
Achieved record 2025 results with 3.2 million procedures, strong global expansion, and a successful da Vinci 5 launch. Focus remains on digital innovation, AI integration, and expanding minimally invasive procedures worldwide, with 2026 guidance targeting 13%-15% procedure growth.
Fiscal Year 2025
-
2025 saw 21% revenue growth, strong global procedure expansion, and robust adoption of da Vinci 5 and Ion platforms. 2026 guidance anticipates 13%-15% procedure growth, stable margins, and continued investment in R&D amid macro and competitive pressures.
-
Q3 2025 delivered 20% global procedure growth, 23% revenue growth, and strong Da Vinci 5 adoption, with upgrades and international placements driving results. Guidance for 2025 was raised, and new digital and clinical advances were highlighted.
-
Q2 saw 21% revenue growth, strong procedure and system placement gains, and robust adoption of new platforms despite international macro challenges. 2025 guidance was raised for procedure growth and gross margin, with continued investment in innovation and manufacturing capacity.
-
The meeting covered board elections, approval of executive compensation, auditor ratification, and strategic updates. Financial performance was strong, with double-digit growth in revenue and procedures. Shareholder proposals on executive pay and golden parachutes were rejected.
-
Q1 saw 19% revenue growth, strong U.S. and international procedure volumes, and robust adoption of new platforms. Full-year procedure growth guidance was raised to 15%-17%, but tariff impacts and OUS capital constraints remain key risks.
-
Strong procedure and revenue growth was driven by new platform launches, international expansion, and recurring revenue. Technological advances in AI, force feedback, and data science are set to transform surgical outcomes. Full global launch of da Vinci 5 and continued investment in innovation and scale are key 2025 priorities.
Fiscal Year 2024
-
2024 saw robust revenue and net income growth, driven by strong da Vinci 5 adoption and global procedure expansion. 2025 guidance anticipates slower margin growth due to higher depreciation, product mix, and FX, with continued R&D investment and cautious outlook for China and Europe.
-
Q3 2024 delivered 17% revenue growth, robust procedure and system expansion, and strong margins, with da Vinci 5 and Ion platforms driving innovation. Guidance for 2024 was raised, but headwinds persist in Asia and Europe due to market pressures.
-
Da Vinci 5 placements are progressing with strong surgeon feedback, and broad launch is expected by mid-2025. Financial performance remains robust, with stable U.S. demand, margin tailwinds from trade-ins, and ongoing expansion in key procedures and geographies.
-
Q2 2024 delivered 17% procedure growth and 14% revenue growth, driven by strong adoption of da Vinci 5, Ion, and SP platforms. Guidance for full-year procedure growth was raised, with gross margin and operating expense outlooks improved. Key risks include bariatric softness and China headwinds.